Speed-to-market is one of the key concerns for any biosimilar company 
looking for expansion. By 2015, sales of biosimilars are expected to reach 
between USD 1.9 to 2.6 billion. To be part of this tidal growth it is important 
to tactically analyse markets to develop win-win strategies for market entry, 
profitable pricing and concrete marketing mediums for commercialisation of 
biosimilars.

    Against this backdrop, CPhI India is launching Commercialisation of 
Biosimilars 2012, a strategic initiative focusing on the most critical issues 
pertaining to biosimilars commercialisation in different markets. This event 
will take place from 1-2 November at The Chancery Pavilion in Bangalore, India 
and will provide speedy market entry strategies, effective licensing 
agreements, profitable pricing models, successful marketing and branding 
strategies and access to key markets like US, UK, China and LATAM.

    Commercialisation of Biosimilars 2012 has on board eminent speakers such as 
Alan Sheppard, Principal Thought Leadership, Global Generics, IMS Health; 
Orlando Vitor Silva, Head Corporate Affairs, Merck Brazil; Tetsuya Takada, 
President, TIPharms & Company Japan; Allan Riting Liu, Vice President/Senior 
Advisor, Wanbang Biopharmaceutical Group China; Purnima Sharma, Chief Executive 
Officer, Biotech Consortium India Limited (BCIL); Subir Basak, President - 
Global Drug Discovery Services, Jubilant Life Sciences; Ranjan
Chakravarti, Senior Vice President Global Strategy, Ranbaxy and Purvish M 
Parikh, President, Indian Society of Medical & Pediatric Oncology among other 
industry experts, all of whom are at the centre stage of the development of 
effective commercialisation strategies globally.

    This event will bring together Heads of Business Development, Marketing, 
Licensing and Strategy from Biopharmaceutical Manufacturers. This initiative 
will help to increase awareness about profitable pricing and latest marketing 
mediums to effectively enter new markets and ensure profitable strategies. To 
know more about Commercialisation of Biosimilars 2012, visit 
http://www.commercialisationofbiosimilars.com/pr.

    CPhI is a UBM brand, and is the largest and most important meeting place 
for the Indian pharma industry. Each year CPhI attracts around 850 exhibitors 
and 30,000 visitors to the show, providing us with an unrivalled reach to all 
the key decision makers in the Indian Pharma industry.

    UBM is a global live media and B2B communications, marketing service and 
data provider founded in 1918. We help organisations make connections, 
communicate their proposition and do business effectively. We enable 
professional people in more than 40 countries around the world to connect and 
engage with each other, with the markets they serve and with the
information they need to succeed. And we do this by whatever means works best 
-at live events, through digital media or in publications. Company Size: 
6000-6500 employees;

Website: http://www.ubm.com.

    For further information please contact:
    Ms Asan Bano
    CPhI Conferences
    +91-(022)-4046-1466
    conferences-india@ubm.com

    SOURCE: CPhI